105 related articles for article (PubMed ID: 35308307)
1. Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients.
Wang Y; Chen Y; Zhou X
Can J Infect Dis Med Microbiol; 2022; 2022():6375870. PubMed ID: 35308307
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab treatment in COVID-19: A single center experience.
Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
[TBL] [Abstract][Full Text] [Related]
3. Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6.
Li P; Lu Z; Li Q; Wang Z; Guo Y; Cai C; Wang S; Liu P; Su X; Huang Y; Dong Y; Qiu W; Ling Y; Yarmus L; Luo F; Zeng L; Bai C; Zhang W
Front Mol Biosci; 2021; 8():651662. PubMed ID: 33937333
[TBL] [Abstract][Full Text] [Related]
4. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.
Bhandari S; Rankawat G; Singh A
Indian J Crit Care Med; 2021 Mar; 25(3):260-266. PubMed ID: 33790504
[No Abstract] [Full Text] [Related]
6. Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan.
Hassan M; Syed F; Zafar M; Iqbal M; Khan NU; Mushtaq HF; Badshah M
Cureus; 2021 Dec; 13(12):e20219. PubMed ID: 35004038
[TBL] [Abstract][Full Text] [Related]
7. Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study.
Hafez W; Ziade MA; Arya A; Saleh H; Abdelshakor M; Fadl Alla O; Agrawal P; Ali S; Rao SR; Gupta S; Abdelli I; Sebastian H; Ali M; Gador M; Al Baha Z; Abdelrahman A
Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203844
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience of tocilizumab treatment among a cohort of patients with COVID-19 infection from Western India.
Surana PD; Nayak R; Sheikh A; Haldankar P; Kale J
J Family Med Prim Care; 2022 Jan; 11(1):123-132. PubMed ID: 35309657
[TBL] [Abstract][Full Text] [Related]
9. Treatment With Tocilizumab for Patients With COVID-19 Infections: A Case-Series Study.
Mo Y; Adarkwah O; Zeibeq J; Pinelis E; Orsini J; Gasperino J
J Clin Pharmacol; 2021 Mar; 61(3):406-411. PubMed ID: 33180360
[TBL] [Abstract][Full Text] [Related]
10. A single-center experience of early administration of tocilizumab and corticosteroids in patients with COVID-19 pneumonia.
Milošević I; Barać A; Jovanović J; Vujović A; Stevanović G; Todorović N; Milošević B
Trans R Soc Trop Med Hyg; 2023 Sep; 117(9):668-672. PubMed ID: 37103332
[TBL] [Abstract][Full Text] [Related]
11. Appropriate use of tocilizumab in COVID-19 infection.
Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
[TBL] [Abstract][Full Text] [Related]
12. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study.
Kardos Z; Szabó M; Baráth Z; Miksi Á; Oláh C; Kozma Á; Gergely JA; Csánky E; Szekanecz Z
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830885
[No Abstract] [Full Text] [Related]
14. Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.
Fomina DS; Lysenko MA; Beloglazova IP; Mutovina ZY; Poteshkina NG; Samsonova IV; Kruglova TS; Chernov AA; Karaulov AV
Pathog Immun; 2020; 5(1):327-341. PubMed ID: 33089038
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).
Colaneri M; Bogliolo L; Valsecchi P; Sacchi P; Zuccaro V; Brandolino F; Montecucco C; Mojoli F; Giusti EM; Bruno R; The Covid Irccs San Matteo Pavia Task Force
Microorganisms; 2020 May; 8(5):. PubMed ID: 32397399
[No Abstract] [Full Text] [Related]
16. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Tocilizumab in Severely Ill COVID-19 Patients With Rapid Respiratory Deterioration: A Single Center Experience During the Third Pandemic Wave in Greece.
Rapti V; Livanou ME; Kollias A; Koutouratsas T; Savranakis O; Sakka V; Nitsotolis T; Kakalou E; Athanasiou K; Syrigos KN; Poulakou G
In Vivo; 2023; 37(3):1312-1317. PubMed ID: 37103076
[TBL] [Abstract][Full Text] [Related]
18. Appropriate Use of Tocilizumab in COVID-19: Early Use is Beneficial.
Altunal LN; Aydın M; Özel AS; Çam G
Infect Dis Clin Microbiol; 2022 Jun; 4(2):116-121. PubMed ID: 38633336
[TBL] [Abstract][Full Text] [Related]
19. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
[TBL] [Abstract][Full Text] [Related]
20. Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia.
Alex R; Gulam SM; Kumar K
Adv Virol; 2022; 2022():7060466. PubMed ID: 35721667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
